151 related articles for article (PubMed ID: 32845191)
1. Pricing methods in outcome-based contracting: δ3: reference-based pricing.
Alkhatib NS; Erstad B; Ramos K; McBride A; Bhattacharjee S; Slack M; Abraham I
J Med Econ; 2020 Nov; 23(11):1230-1236. PubMed ID: 32845191
[TBL] [Abstract][Full Text] [Related]
2. Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing.
Alkhatib NS; McBride A; Bhattacharjee S; Ramos K; Erstad B; Slack M; Billheimer D; Abraham I
J Med Econ; 2020 Nov; 23(11):1246-1255. PubMed ID: 32845204
[TBL] [Abstract][Full Text] [Related]
3. Pricing methods in outcome-based contracting: δ6: adherence-based pricing.
Alkhatib NS; Slack M; Bhattacharjee S; Erstad B; Ramos K; McBride A; Abraham I
J Med Econ; 2020 Nov; 23(11):1256-1265. PubMed ID: 32845209
[TBL] [Abstract][Full Text] [Related]
4. Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing.
Alkhatib NS; Ramos K; Erstad B; Slack M; McBride A; Bhattacharjee S; Abraham I
J Med Econ; 2020 Nov; 23(11):1223-1229. PubMed ID: 32845201
[TBL] [Abstract][Full Text] [Related]
5. Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs).
Alkhatib NS; McBride A; Slack M; Bhattacharjee S; Erstad B; Ramos K; Abraham I
J Med Econ; 2020 Nov; 23(11):1266-1272. PubMed ID: 32845180
[TBL] [Abstract][Full Text] [Related]
6. Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing.
Alkhatib NS; Ramos K; Erstad B; Slack M; McBride A; Bhattacharjee S; Abraham I
J Med Econ; 2020 Nov; 23(11):1215-1222. PubMed ID: 32845794
[TBL] [Abstract][Full Text] [Related]
7. Pricing methods in outcome-based contracting: δ4: safety-based pricing.
Alkhatib NS; Bhattacharjee S; McBride A; Ramos K; Slack M; Erstad B; Abraham I
J Med Econ; 2020 Nov; 23(11):1237-1245. PubMed ID: 32845205
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Alós-Almiñana M; Cortijo J
J Comp Eff Res; 2019 Aug; 8(11):853-863. PubMed ID: 31478399
[No Abstract] [Full Text] [Related]
12. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
Westerink L; Nicolai JLJ; Samuelsen C; Smit HJM; Postmus PE; Griebsch I; Postma MJ
Eur J Health Econ; 2020 Aug; 21(6):931-943. PubMed ID: 32328874
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
14. How sustainable are new treatment strategies for NSCLC?
Remon J; Lopes G; Camps C
Lancet Respir Med; 2019 Sep; 7(9):733-735. PubMed ID: 31208953
[No Abstract] [Full Text] [Related]
15. [Drug approval: Osimertinib as an adjuvant treatment of non-small cell lung carcinoma with EFGR mutation after complete resection].
Chevassut D; Duchemann B
Bull Cancer; 2021 Dec; 108(12):1072-1073. PubMed ID: 34702549
[No Abstract] [Full Text] [Related]
16. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.
Cao F; Gong YB; Kang XH; Lu ZH; Wang Y; Zhao KL; Miao ZH; Liao MJ; Xu ZY
Toxicol Appl Pharmacol; 2019 Sep; 379():114662. PubMed ID: 31301315
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
Khoo T; Gao L
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
[No Abstract] [Full Text] [Related]
19. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
Wu B; Gu X; Zhang Q; Xie F
Oncologist; 2019 Mar; 24(3):349-357. PubMed ID: 30257889
[TBL] [Abstract][Full Text] [Related]
20. Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
Gyawali B; West HJ
J Clin Oncol; 2021 Jan; 39(3):175-177. PubMed ID: 33275490
[No Abstract] [Full Text] [Related]
[Next] [New Search]
